MAA Laboratories Joins FDA Emerging Technologies Program with NanoCont™ Platform
August 15, 2024 – Durham, NC
MAA Laboratories is pleased to announce its acceptance into the FDA’s Emerging Technologies Program (ETP) for its cutting-edge NanoCont™ platform. Participation in the program opens a new avenue for communication with FDA experts, significantly benefiting the application of our proprietary drug delivery technology. The NanoCont™ platform, known for its nanoparticle approach and advanced manufacturing techniques, aligns with Quality by Design and Continuous Manufacturing principles. ETP membership facilitates early feedback, streamlined reviews, and regulatory clarity, enhancing our development strategy and market appeal. This is another indication of the value of NanoCont™ as an innovation in pharmaceutical technology.
For press and other inquiries, please contact:
Corporate Office
MAA Laboratories, Inc.
400 Park Offices Drive
Suite# 214
Durham, NC 27709
United States of America
Email: info@maalaboratories.com
Phone: 919.271.7868
MAA Laboratories to attend the BIO International Convention 2018
May 21, 2018 – Raleigh, NC
The MAA Laboratories team will attend the BIO 2018 convention on June 4-7 in Boston. For inquiries related to product licensing and development partnerships, or to arrange a meeting with MAA Laboratories, please contact our business development team at BD@maalaboratories.com.
For press and other inquiries, please contact:
Corporate Office
MAA Laboratories, Inc.
400 Park Offices Drive
Suite# 214
Durham, NC 27709
United States of America
Email: info@maalaboratories.com
Phone: 919.271.7868
MAA Laboratories to attend the JP Morgan Healthcare Conference
January 2, 2018 – Raleigh, NC
The MAA Laboratories team will attend the 36th annual JP Morgan Healthcare Conference on January 8 – 11 in San Francisco, California. For inquiries related to product licensing and development partnerships, or to arrange a meeting with MAA Laboratories, please contact our business development team at BD@maalaboratories.com.
For press and other inquiries, please contact:
Corporate Office
MAA Laboratories, Inc.
400 Park Offices Drive
Suite# 214
Durham, NC 27709
United States of America
Email: info@maalaboratories.com
Phone: 919.271.7868
MAA Laboratories awarded NIH Phase I SBIR grant
September 19, 2017 – Raleigh, NC
MAA Laboratories has been awarded an NIH Phase I Small Business Innovation Research (SBIR) grant. Awarded via the National Cancer Institute, an institute of the NIH, the SBIR grant will provide non-dilutive funding to MAA Laboratories to develop a novel formulation of an anti-leukemia drug product, which currently has significant deficiencies related to dosing and bioavailability.The goal of the project is to use MAA’s proprietary NanoContTM technology to create an anti-leukemia drug product with markedly improve performance, which will provide an improved therapeutic option for patients with leukemia.
MAA Laboratories receives SBIR Matching Funds from the One N.C. Small Business Program
August 30, 2017 – Raleigh, NC
MAA Laboratories has received a grant from the One N.C. Small Business Program. The award is based on the successful funding of MAA Laboratories’ Phase I SBIR grant from the National Science Foundation. The NSF SBIR grant was funded to further develop the company’s NanoContTM drug development technology. One N.C. matching funds will be used to accelerate the development of MAA Laboratories pipeline products through pre-clinical testing.